Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes
Introduction To investigate the risk factors for the death in patients with COVID-19 with type 2 diabetes mellitus (T2DM).Research design and methods We retrospectively enrolled inpatients with COVID-19 from Wuhan Jinyintan Hospital (Wuhan, China) between December 25, 2019, and March 3, 2020. The ep...
Main Authors: | , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-12-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/8/2/e001851.full |
id |
doaj-136f7b7ae7414456be921d904153e2b7 |
---|---|
record_format |
Article |
spelling |
doaj-136f7b7ae7414456be921d904153e2b72021-01-22T02:30:15ZengBMJ Publishing GroupBMJ Open Diabetes Research & Care2052-48972020-12-018210.1136/bmjdrc-2020-001851Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetesYing Chen0Jie Xu1Xiaoyan Chen2Chaomin Wu3Ming Wei4Yen-cheng Chao5Juan Song6Dongni Hou7Yuye Zhang8Chunling Du9Xiaoying Li10Yuanlin Song11Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Infectious Diseases, Fengxian Guhua Hospital, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaTuberculosis and Respiratory Department, Wuhan Jinyintan Hospital, Wuhan, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Qingpu Branch, Shanghai, ChinaDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai, ChinaIntroduction To investigate the risk factors for the death in patients with COVID-19 with type 2 diabetes mellitus (T2DM).Research design and methods We retrospectively enrolled inpatients with COVID-19 from Wuhan Jinyintan Hospital (Wuhan, China) between December 25, 2019, and March 3, 2020. The epidemiological and clinical data were compared between non-T2DM and T2DM or between survivors and non-survivors. Univariable and multivariable Cox regression analyses were used to explore the effect of T2DM and complications on in-hospital death.Results A total of 1105 inpatients with COVID-19, 967 subjects with without T2DM (n=522 male, 54.0%) and 138 subjects with pre-existing T2DM (n=82 male, 59.4%) were included for baseline characteristics analyses. The complications were also markedly increased in patients with pre-existing T2DM, including acute respiratory distress syndrome (ARDS) (48.6% vs 32.3%, p<0.001), acute cardiac injury (ACI) (36.2% vs 16.7%, p<0.001), acute kidney injury (AKI) (24.8% vs 9.5%, p<0.001), coagulopathy (24.8% vs 11.1%, p<0.001), and hypoproteinemia (21.2% vs 9.4%, p<0.001). The in-hospital mortality was significantly higher in patients with pre-existing T2DM compared with those without T2DM (35.3% vs 17.4%, p<0.001). Moreover, in hospitalized patients with COVID-19 with T2DM, ARDS and coagulopathy were the main causes of mortality, with an HR of 7.96 (95% CI 2.25 to 28.24, p=0.001) for ARDS and an HR of 2.37 (95% CI 1.08 to 5.21, p=0.032) for coagulopathy. This was different from inpatients with COVID-19 without T2DM, in whom ARDS and cardiac injury were the main causes of mortality, with an HR of 12.18 (95% CI 5.74 to 25.89, p<0.001) for ARDS and an HR of 4.42 (95% CI 2.73 to 7.15, p<0.001) for cardiac injury.Conclusions Coagulopathy was a major extrapulmonary risk factor for death in inpatients with COVID-19 with T2DM rather than ACI and AKI, which were well associated with mortality in inpatients with COVID-19 without T2DM.https://drc.bmj.com/content/8/2/e001851.full |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ying Chen Jie Xu Xiaoyan Chen Chaomin Wu Ming Wei Yen-cheng Chao Juan Song Dongni Hou Yuye Zhang Chunling Du Xiaoying Li Yuanlin Song |
spellingShingle |
Ying Chen Jie Xu Xiaoyan Chen Chaomin Wu Ming Wei Yen-cheng Chao Juan Song Dongni Hou Yuye Zhang Chunling Du Xiaoying Li Yuanlin Song Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes BMJ Open Diabetes Research & Care |
author_facet |
Ying Chen Jie Xu Xiaoyan Chen Chaomin Wu Ming Wei Yen-cheng Chao Juan Song Dongni Hou Yuye Zhang Chunling Du Xiaoying Li Yuanlin Song |
author_sort |
Ying Chen |
title |
Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
title_short |
Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
title_full |
Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
title_fullStr |
Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
title_full_unstemmed |
Coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with COVID-19 with type 2 diabetes |
title_sort |
coagulopathy is a major extrapulmonary risk factor for mortality in hospitalized patients with covid-19 with type 2 diabetes |
publisher |
BMJ Publishing Group |
series |
BMJ Open Diabetes Research & Care |
issn |
2052-4897 |
publishDate |
2020-12-01 |
description |
Introduction To investigate the risk factors for the death in patients with COVID-19 with type 2 diabetes mellitus (T2DM).Research design and methods We retrospectively enrolled inpatients with COVID-19 from Wuhan Jinyintan Hospital (Wuhan, China) between December 25, 2019, and March 3, 2020. The epidemiological and clinical data were compared between non-T2DM and T2DM or between survivors and non-survivors. Univariable and multivariable Cox regression analyses were used to explore the effect of T2DM and complications on in-hospital death.Results A total of 1105 inpatients with COVID-19, 967 subjects with without T2DM (n=522 male, 54.0%) and 138 subjects with pre-existing T2DM (n=82 male, 59.4%) were included for baseline characteristics analyses. The complications were also markedly increased in patients with pre-existing T2DM, including acute respiratory distress syndrome (ARDS) (48.6% vs 32.3%, p<0.001), acute cardiac injury (ACI) (36.2% vs 16.7%, p<0.001), acute kidney injury (AKI) (24.8% vs 9.5%, p<0.001), coagulopathy (24.8% vs 11.1%, p<0.001), and hypoproteinemia (21.2% vs 9.4%, p<0.001). The in-hospital mortality was significantly higher in patients with pre-existing T2DM compared with those without T2DM (35.3% vs 17.4%, p<0.001). Moreover, in hospitalized patients with COVID-19 with T2DM, ARDS and coagulopathy were the main causes of mortality, with an HR of 7.96 (95% CI 2.25 to 28.24, p=0.001) for ARDS and an HR of 2.37 (95% CI 1.08 to 5.21, p=0.032) for coagulopathy. This was different from inpatients with COVID-19 without T2DM, in whom ARDS and cardiac injury were the main causes of mortality, with an HR of 12.18 (95% CI 5.74 to 25.89, p<0.001) for ARDS and an HR of 4.42 (95% CI 2.73 to 7.15, p<0.001) for cardiac injury.Conclusions Coagulopathy was a major extrapulmonary risk factor for death in inpatients with COVID-19 with T2DM rather than ACI and AKI, which were well associated with mortality in inpatients with COVID-19 without T2DM. |
url |
https://drc.bmj.com/content/8/2/e001851.full |
work_keys_str_mv |
AT yingchen coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT jiexu coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT xiaoyanchen coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT chaominwu coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT mingwei coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT yenchengchao coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT juansong coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT dongnihou coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT yuyezhang coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT chunlingdu coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT xiaoyingli coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes AT yuanlinsong coagulopathyisamajorextrapulmonaryriskfactorformortalityinhospitalizedpatientswithcovid19withtype2diabetes |
_version_ |
1724329315606200320 |